Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model
about
Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes.PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
P2860
Q37126489-EBF009F7-DE14-4B67-9EEC-73DB42F1756EQ37607932-38454FAB-1969-4FDA-B1F3-7818A0148781Q38621024-ABB21858-91F3-471F-A1DB-4ADD9B4496F4Q47333263-789A30BF-9F4C-49BB-9FB0-8D2AB56DA763Q47592224-FFCE0EF3-69C9-4807-BAB1-78BC3C45A37AQ47664709-4ACAA061-6AE3-4780-8234-C0AC0656F8E8Q49719905-538BB3D2-2D38-4C70-A40E-965D6CFCAC50Q54178349-CA2AC1C8-C732-46CA-9E7B-49CC2B1C9CEFQ55053782-23C5F557-11F5-45DA-B367-A5D8F99C0CA6Q58758044-9188B204-E2C8-425C-A7B1-5EB18F470464
P2860
Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Prediction of Drug-Drug Intera ...... ologically Based Dynamic Model
@en
type
label
Prediction of Drug-Drug Intera ...... ologically Based Dynamic Model
@en
prefLabel
Prediction of Drug-Drug Intera ...... ologically Based Dynamic Model
@en
P2093
P2860
P356
P1476
Prediction of Drug-Drug Intera ...... ologically Based Dynamic Model
@en
P2093
Iain Gardner
Jane R Kenny
Karen Rowland-Yeo
Krystle Okialda
Lisa M Almond
Masoud Jamei
Oliver Hatley
Sophie Mukadam
Susan Wong
Suzanne Tay
P2860
P304
P356
10.1124/DMD.115.066845
P577
2016-03-29T00:00:00Z